• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Rapid promyelocytic blast crisis of chronic myeloid leukemia with PML-RARα fusion gene: a case report and literature review].

作者信息

Liu M S, Han X Y, Qu Z G, Luo Q L, Wu K L, Chen J, Wu Y J, Xu W L, Yang X X, Zhu Y Y

机构信息

Yiwu Central Hospital, Yiwu 322099, China.

The First Affiliated Hospital, Zhejiang University, Hangzhou 310003, China.

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2023 Jun 14;44(6):512-515. doi: 10.3760/cma.j.issn.0253-2727.2023.06.014.

DOI:10.3760/cma.j.issn.0253-2727.2023.06.014
PMID:37550211
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10450556/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba26/10450556/f14ffac45576/cjh-44-06-512-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba26/10450556/f14ffac45576/cjh-44-06-512-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba26/10450556/f14ffac45576/cjh-44-06-512-g001.jpg

相似文献

1
[Rapid promyelocytic blast crisis of chronic myeloid leukemia with PML-RARα fusion gene: a case report and literature review].[慢性髓系白血病伴PML-RARα融合基因的急早幼粒细胞白血病母细胞危象：一例报告及文献复习]
Zhonghua Xue Ye Xue Za Zhi. 2023 Jun 14;44(6):512-515. doi: 10.3760/cma.j.issn.0253-2727.2023.06.014.
2
Identification of B94 (TNFAIP2) as a potential retinoic acid target gene in acute promyelocytic leukemia.鉴定B94（TNFAIP2）为急性早幼粒细胞白血病中潜在的视黄酸靶基因。
Cancer Res. 2000 Apr 1;60(7):1824-9.
3
Acute promyelocytic leukemia and variant fusion proteins: PLZF-RARα fusion protein at a glance.急性早幼粒细胞白血病和变异融合蛋白：PLZF-RARα 融合蛋白一览。
Semin Oncol. 2019 Apr;46(2):133-144. doi: 10.1053/j.seminoncol.2019.04.004. Epub 2019 May 7.
4
Targeting of PML/RARalpha is lethal to retinoic acid-resistant promyelocytic leukemia cells.靶向PML/RARα对维甲酸耐药的早幼粒细胞白血病细胞具有致死性。
Blood. 1998 Sep 1;92(5):1758-67.
5
Annexin A2-S100A10 heterotetramer is upregulated by PML/RARα fusion protein and promotes plasminogen-dependent fibrinolysis and matrix invasion in acute promyelocytic leukemia.膜联蛋白 A2-S100A10 异四聚体受 PML/RARα 融合蛋白上调，促进急性早幼粒细胞白血病中纤溶酶原依赖性纤维蛋白溶解和基质侵袭。
Front Med. 2017 Sep;11(3):410-422. doi: 10.1007/s11684-017-0527-6. Epub 2017 Jul 8.
6
Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF-RARalpha and NPM-RARalpha.转基因小鼠中不同的白血病表型以及早幼粒细胞白血病变异融合基因PLZF-RARα和NPM-RARα产生的不同共抑制因子相互作用。
Proc Natl Acad Sci U S A. 1999 May 25;96(11):6318-23. doi: 10.1073/pnas.96.11.6318.
7
PML/RARalpha, a fusion protein in acute promyelocytic leukemia, prevents growth factor withdrawal-induced apoptosis in TF-1 cells.PML/RARα是急性早幼粒细胞白血病中的一种融合蛋白，可防止TF-1细胞中生长因子撤除诱导的细胞凋亡。
Clin Cancer Res. 1995 Jun;1(6):583-90.
8
Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia.核受体共抑制因子与早幼粒细胞白血病（PML）及早幼粒细胞白血病锌指蛋白（PLZF）-维甲酸受体α（RARα）结合时视黄酸敏感性降低是急性早幼粒细胞白血病分子发病机制及治疗的基础。
Blood. 1998 Apr 15;91(8):2634-42.
9
Acute promyelocytic leukemia: a novel PML/RARalpha fusion that generates a frameshift in the RARalpha transcript and ATRA resistance.急性早幼粒细胞白血病：一种新型的PML/RARα融合基因，该融合基因导致维甲酸受体α（RARα）转录本发生移码突变并产生全反式维甲酸（ATRA）耐药。
Leuk Lymphoma. 2007 Mar;48(3):489-96. doi: 10.1080/10428190601136163.
10
Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein.半胱天冬酶介导维甲酸诱导的急性早幼粒细胞白血病PML/RARα融合蛋白的降解。
Blood. 1998 Oct 1;92(7):2244-51.

引用本文的文献

1
An important oversight in the World Health Organization diagnostic classification: chronic myeloid leukemia with the fusion clone.世界卫生组织诊断分类中的一个重要疏忽：伴有融合克隆的慢性髓性白血病。
Haematologica. 2024 Dec 1;109(12):4120-4124. doi: 10.3324/haematol.2024.285562.

本文引用的文献

1
Fusion Transcripts Detectable 8 Months prior to Promyelocytic Blast Crisis in Chronic Myeloid Leukemia.在慢性髓性白血病早幼粒细胞急变期前8个月可检测到融合转录本。
Case Rep Hematol. 2020 Sep 1;2020:8830595. doi: 10.1155/2020/8830595. eCollection 2020.
2
All--retinoic-acid and arsenic trioxide induced remission in promyelocytic blast crisis.全反式维甲酸和三氧化二砷可诱导早幼粒细胞白血病急变期缓解。
Leuk Res Rep. 2018 Jul 25;10:16-19. doi: 10.1016/j.lrr.2018.07.002. eCollection 2018.
3
Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
酪氨酸激酶抑制剂时代慢性髓性白血病急变期患者的预后因素及生存结果：477例患者的队列研究
Cancer. 2017 Nov 15;123(22):4391-4402. doi: 10.1002/cncr.30864. Epub 2017 Jul 25.
4
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.一线尼罗替尼与伊马替尼治疗慢性期慢性髓性白血病的长期获益与风险：随机ENESTnd试验的5年更新
Leukemia. 2016 May;30(5):1044-54. doi: 10.1038/leu.2016.5. Epub 2016 Feb 3.
5
Promyelocytic Blastic Crisis in Chronic Myeloid Leukemia During Imatinib Treatment.伊马替尼治疗慢性髓性白血病期间的早幼粒细胞白血病急变期
Turk J Haematol. 2015 Jun;32(2):193-4. doi: 10.4274/tjh.2014.0211.
6
Natural course and biology of CML.慢性粒细胞白血病的自然病程与生物学特性
Ann Hematol. 2015 Apr;94 Suppl 2:S107-21. doi: 10.1007/s00277-015-2325-z. Epub 2015 Mar 27.
7
Blast phase in chronic myelogenous leukemia is skewed toward unusual blast types in patients treated with tyrosine kinase inhibitors: a comparative study of 67 cases.慢性髓性白血病急变期患者接受酪氨酸激酶抑制剂治疗后，急变类型偏向不常见类型：67例病例的比较研究
Am J Clin Pathol. 2015 Jan;143(1):105-19. doi: 10.1309/AJCPWEX5YY4PHSCN.
8
Promyelocytic blast crisis of chronic myelogenous leukemia.慢性粒细胞白血病的早幼粒细胞原始细胞危象
Blood. 2012 Nov 8;120(19):3873. doi: 10.1182/blood-2012-07-433136.
9
Successful management with an effective induction regimen followed by allogeneic hematopoietic stem cell transplantation for promyelocytic blast crisis of chronic myelogenous leukemia.
Ann Hematol. 2012 Apr;91(4):621-3. doi: 10.1007/s00277-011-1269-1. Epub 2011 Jun 4.
10
Successful imatinib and arsenic trioxide combination therapy for sudden onset promyelocytic crisis with t(15;17) in chronic myeloid leukemia.伊马替尼与三氧化二砷联合治疗慢性粒细胞白血病伴t(15;17)的急性早幼粒细胞危象成功。
Leuk Res. 2010 Aug;34(8):e213-4. doi: 10.1016/j.leukres.2010.02.030. Epub 2010 Mar 17.